Abstract 4287: GBC-11004: an AI-driven novel kinase target with potential to overcome osimertinib resistance in NSCLC

作者
Hat Nim Jeon,Ji Young Bae,Hyunsun Na,Ji-Hwan Park,Seung Hyun Ahn,Bada Pyo,Jihye Ryu,Jinguen Rheey
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_1): 4287-4287
标识
DOI:10.1158/1538-7445.am2025-4287
摘要

Abstract Osimertinib resistance poses a significant clinical challenge in the treatment of non-small cell lung cancer (NSCLC), with diverse mechanisms complicating patient outcomes. Conventional next-generation sequencing (NGS) analysis methods often fall short in identifying effective therapeutic targets due to the complexity and heterogeneity of resistance mechanisms. To address this issue, we have developed an artificial intelligence (AI)-driven target discovery platform designed to identify novel and effective drug target genes capable of overcoming Osimertinib resistance in NSCLC, thereby surpassing the capabilities of traditional NGS analysis. Our platform integrates three key components: deep learning (G-TAC), statistical significance testing (G-SET), and a large language model (G-LAT). G-TAC and G-SET evaluate and rank genes according to their responsiveness to Osimertinib and tumor-specific expression. G-LAT assesses these genes based on publications and clinical trials to ensure novelty and efficacy of the identified targets. We identified a novel kinase target named GBC-11004, as one of the top-ranked target genes that were found to be overexpressed in patient-derived organoids (PDOs) resistant to Osimertinib. To ascertain the functional impact of GBC-11004, target validation was conducted using PDOs and CRISPR/Cas9-based gene editing. Gene editing in Osimertinib resistant PDOs resulted in a significant decrease in cell viability corresponding to increased indel frequency. Furthermore, we have initiated lead compound optimization by preliminary IC50 analyses using compounds targeting GBC-11004 and observed significantly enhanced sensitivity in the combination therapy group (Osimertinib + GBC-11004 inhibitor) compared to the Osimertinib monotherapy group in resistant PDO models. Our results demonstrate the potential of GBC-11004 as a novel therapeutic target for overcoming Osimertinib resistance in NSCLC treatment and emphasize the capability of our PDO-based AI-driven target discovery platform in identifying high-priority novel targets. Citation Format: Hat Nim Jeon, Ji Young Bae, Hyunsun Na, Ji Hwan Park, Seung Hyun Ahn, Bada Pyo, Jihye Ryu, Jinguen Rheey. GBC-11004: an AI-driven novel kinase target with potential to overcome osimertinib resistance in NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4287.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
闪闪灵完成签到 ,获得积分10
1秒前
WRZ完成签到 ,获得积分10
1秒前
1秒前
坏坏完成签到,获得积分10
3秒前
3秒前
素龙宝宝发布了新的文献求助10
3秒前
dsfd完成签到,获得积分10
4秒前
4秒前
打打的应助被宝蓝调调采纳,获得10
4秒前
温柔樱桃完成签到 ,获得积分10
5秒前
叶长亭完成签到,获得积分10
6秒前
6秒前
DW的应助被wang采纳,获得10
6秒前
6秒前
6秒前
丘比特的应助被Rbb采纳,获得10
6秒前
梦梦梦发布了新的文献求助10
6秒前
lulu完成签到,获得积分10
6秒前
7秒前
sing完成签到,获得积分10
8秒前
jennawu完成签到 ,获得积分10
8秒前
8秒前
8秒前
9秒前
叶长亭发布了新的文献求助10
9秒前
9秒前
顺利的翠完成签到,获得积分10
9秒前
红雨灰衣完成签到 ,获得积分10
10秒前
18746005898完成签到 ,获得积分10
10秒前
jiang完成签到 ,获得积分10
10秒前
bhsadhusu完成签到 ,获得积分10
11秒前
Xia发布了新的文献求助10
12秒前
共享精神的应助被梦梦梦采纳,获得10
13秒前
激昂的玫瑰完成签到 ,获得积分10
14秒前
酷炫的盼海完成签到,获得积分20
15秒前
15秒前
15秒前
哈哈哈发布了新的文献求助10
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168163
求助须知:如何正确求助?哪些是违规求助? 9561243
关于积分的说明 21759855
捐赠科研通 7759477
什么是DOI,文献DOI怎么找? 3429959
关于科研通互助平台的介绍 2553757
邀请新用户注册赠送积分活动 2474496